DekaBank Deutsche Girozentrale’s Akero Therapeutics AKRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-20,000
Closed -$532K 1109
2025
Q4
$532K Hold
20,000
﹤0.01% 987
2025
Q3
$949K Hold
20,000
﹤0.01% 884
2025
Q2
$1.14M Hold
20,000
﹤0.01% 839
2025
Q1
$846K Hold
20,000
﹤0.01% 877
2024
Q4
$557K Hold
20,000
﹤0.01% 981
2024
Q3
$559K Hold
20,000
﹤0.01% 993
2024
Q2
$466K Hold
20,000
﹤0.01% 1019
2024
Q1
$488K Sell
20,000
-7,600
-28% -$183K ﹤0.01% 1004
2023
Q4
$659K Hold
27,600
﹤0.01% 984
2023
Q3
$1.33M Buy
27,600
+6,000
+28% +$279K ﹤0.01% 824
2023
Q2
$966K Hold
21,600
﹤0.01% 886
2023
Q1
$812K Buy
21,600
+7,600
+54% +$339K ﹤0.01% 917
2022
Q4
$747K Hold
14,000
﹤0.01% 952
2022
Q3
$417K Buy
+14,000
New +$214K ﹤0.01% 1078
2022
Q2
Sell
-13,500
Closed -$197K 1364
2022
Q1
$197K Buy
13,500
+1,200
+10% +$21K ﹤0.01% 1211
2021
Q4
$261K Buy
12,300
+300
+3% +$6.65K ﹤0.01% 1223
2021
Q3
$266K Hold
12,000
﹤0.01% 1155
2021
Q2
$305K Hold
12,000
﹤0.01% 1141
2021
Q1
$338K Hold
12,000
﹤0.01% 1092
2020
Q4
$301K Buy
+12,000
New +$334K ﹤0.01% 1120

DekaBank Deutsche Girozentrale's AKRO Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Akero Therapeutics (AKRO) in Q1 2026, closing a stake of 20,000 shares — an estimated $532K sold.

DekaBank Deutsche Girozentrale first reported a position in AKRO in Q4 2020 and held it in 20 quarters. The position peaked at $1.33M in Q3 2023. 0 funds tracked by Wall St. Rank hold AKRO as of Q1 2026.

  • DekaBank Deutsche Girozentrale reported no remaining Akero Therapeutics position as of Q1 2026 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 20,000 Akero Therapeutics shares in Q1 2026, an estimated $532K.
  • DekaBank Deutsche Girozentrale first reported a position in Akero Therapeutics in Q4 2020 and held it in 20 quarters.
  • DekaBank Deutsche Girozentrale's Akero Therapeutics position peaked at $1.33M in Q3 2023.
  • 0 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.